Effects of Home Care on patients with hepatocellular carcinoma treated with sorafenib.

Moser, Monika; Radu, Iuliana-Pompilia; Dufour, Jean-François (2021). Effects of Home Care on patients with hepatocellular carcinoma treated with sorafenib. JGH open, 5(8), pp. 864-870. Wiley 10.1002/jgh3.12533

[img]
Preview
Text
JGH3-5-864.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC).

Download (292kB) | Preview

Background and Aim

Treatment with sorafenib causes diverse side effects, which limits adherence. This work assesses whether Home Care, a psychosocial nursing intervention, prolongs the duration of treatment in patients with advanced hepatocellular carcinoma (HCC) and if it influences health-related quality of life (HRQL).

Methods and Results

This is a cohort study using data from patients receiving sorafenib in the prospective Bern HCC Cohort at the University Hospital. Duration of treatment, overall survival, and HRQL using the Functional Assessment of Cancer Therapy-Hepatobiliary questionnaire were compared in the two groups. A total of 173 patients were eligible for the analysis. Among them, 141 were in the Home Care program, and 32 were not. Patients with Home Care had a significantly longer duration of treatment (265 days vs 152 days, P = 0.003) and a better functional well-being (17.7 vs 12.5, P = 0.015).

Conclusion

Psychosocial interventions such as Home Care are a valid method in improving adherence to sorafenib and can therefore be recommended.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Hepatology
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie

UniBE Contributor:

Radu, Iuliana Pompilia, Dufour, Jean-François

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2397-9070

Publisher:

Wiley

Language:

English

Submitter:

Rahel Fuhrer

Date Deposited:

26 Oct 2021 17:50

Last Modified:

05 Dec 2022 15:53

Publisher DOI:

10.1002/jgh3.12533

PubMed ID:

34386593

Uncontrolled Keywords:

liver cancer oncology quality of life sorafenib treatment

BORIS DOI:

10.48350/160184

URI:

https://boris.unibe.ch/id/eprint/160184

Actions (login required)

Edit item Edit item
Provide Feedback